DiA Imaging Analysis Collaborates with Intel Corporation to Accelerate Processing Time of its AI-based Cardiac Ultrasound Software in Hospitals

DiA Imaging Analysis Collaborates with Intel Corporation to Accelerate Processing Time of its AI-based Cardiac Ultrasound Software in Hospitals

DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, has teamed up with Intelto streamline artificial intelligence (AI) solutions used by echocardiography (Echo) labs. DiA’s AI-based software, LVivo Seamless™, automatically analyzes cardiac ultrasound images using the Intel® Distribution of OpenVINO™ toolkit, to optimize processing time by over 40% percent while maintaining accuracy.

The ability to view key cardiac measurements results quickly after each scan is vital to the Echo Lab workflow.

DiA Imaging Analysis LVivo Seamless™ algorithm runs automatically on cardiac ultrasound exams, selecting and analyzing the optimal cardiac views to generate key measurements that help identify clinical indications – that are otherwise difficult to find visually or manually. DiA’s solutions enable sonographers and cardiologists to analyze higher scan volumes in a quicker and reproducible way, optimizing their everyday workflows.

“Intel is committed to creating world-changing technology that helps advance patient care. Our edge-to-cloud infrastructure technology supports rich data analysis environments like DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures. LVivo Seamless, where time and accuracy are crucial elements,” said Alex Flores, Head of  Global Health Solutions at Intel Corporation.

By working with Intel, DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures.

“Every minute counts in a busy echocardiography environment. Using an AI solution like LVivo  Seamless that automatically runs ‘behind the scenes’ on hospital servers eliminates many manual and visual steps involved with both cardiac ultrasound view selection and measurement,” said Hila Goldman Aslan, CEO, and co-founder of DiA Imaging Analysis. “We are thrilled to work closely with Intel, leveraging AI to make the analysis of ultrasound images smarter, faster, and  more accessible.”


DiA Imaging Analysis is a leading provider of FDA-cleared and CE marked ultrasound AI  software solutions that automate the way clinicians use and analyze ultrasound scans. The company’s LVivo product line for cardiac and abdominal auto analysis allows clinicians with varying levels of ultrasound experience to automatically analyze ultrasound images on their ultrasound devices and healthcare IT systems with increased speed, efficiency, and accuracy.  DiA serves thousands of end-users worldwide.  

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.